Real-time MR imaging of adeno-associated viral vector delivery to the primate brain

被引:94
作者
Fiandaca, Massimo S. [1 ]
Varenika, Vanja [1 ]
Eberling, Jamie [1 ,2 ]
McKnight, Tracy [3 ]
Bringas, John [1 ]
Pivirotto, Phillip [1 ]
Beyer, Janine [1 ]
Hadaczek, Piotr [1 ]
Bowers, William [4 ]
Park, John [5 ]
Federoff, Howard [6 ]
Forsayeth, John [1 ]
Bankiewicz, Krystof S. [1 ]
机构
[1] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94103 USA
[2] Univ Calif Berkeley, Lawrence Berkeley Lab, Ctr Funct Imaging, Berkeley, CA 94720 USA
[3] Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94103 USA
[4] Univ Rochester, Rochester, NY USA
[5] Univ Calif San Francisco, Dept Hematol Oncol, San Francisco, CA 94103 USA
[6] Georgetown Univ, Washington, DC USA
关键词
Adeno-associated virus; Gadolinium; Liposomes; Thalamus; Putamen; Corona radiata; CONVECTION-ENHANCED DELIVERY; GENE-THERAPY VECTOR; PARKINSONIAN MONKEYS; RAT-BRAIN; AAV-HAADC; VIRUS; LIPOSOMES; STRIATUM; INFUSION; STEM;
D O I
10.1016/j.neuroimage.2008.11.012
中图分类号
Q189 [神经科学];
学科分类号
071006 [神经生物学];
摘要
We are developing a method for real-time magnetic resonance imaging (MRI) visualization of convection-enhanced delivery (CED) of adeno-associated vital vectors (AAV) to the primate brain. By including gadolinium-loaded liposomes (GDL) with AAV, we can track the convective movement of vital particles by continuous monitoring of distribution of Surrogate GDL. In order to validate this approach, we infused two AAV (AAV1-GFP and AAV2-hAADC) into three different regions of non-human primate brain (corona radiata, putamen, and thalamus). The procedure was tolerated well by all three animals in the study. The distribution of GFP determined by immunohistochemistry in both brain regions correlated closely with distribution of GDL determined by MRI. Co-distribution was weaker with AAV2-hAADC, although in vivo PET scanning with FMT for AADC activity correlated well with immunohistochemistry of AADC. Although this is a relatively small study, it appears that AAV1 correlates better with MRI-monitored delivery than does AAV2. It seems likely that the difference in distribution may be due to differences in tissue specificity of the two serotypes. (C) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:T27 / T35
页数:9
相关论文
共 46 条
[1]
Baekelandt V, 2000, CURR OPIN MOL THER, V2, P540
[2]
Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC [J].
Bankiewicz, Krystof S. ;
Forsayeth, John ;
Eberling, Jamie L. ;
Sanchez-Pernaute, Rosario ;
Pivirotto, Philip ;
Bringas, John ;
Herscovitch, Peter ;
Carson, Richard E. ;
Eckelman, William ;
Reutter, Bryan ;
Cunningham, Janet .
MOLECULAR THERAPY, 2006, 14 (04) :564-570
[3]
BANKIEWICZ KS, 1986, LIFE SCI, V39, P7, DOI 10.1016/0024-3205(86)90431-5
[4]
Convection-enhanced delivery of AAV vector in parkinsonian monkeys;: In vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach [J].
Bankiewicz, KS ;
Eberling, JL ;
Kohutnicka, M ;
Jagust, W ;
Pivirotto, P ;
Bringas, J ;
Cunningham, J ;
Budinger, TF ;
Harvey-White, J .
EXPERIMENTAL NEUROLOGY, 2000, 164 (01) :2-14
[5]
CONVECTION-ENHANCED DELIVERY OF MACROMOLECULES IN THE BRAIN [J].
BOBO, RH ;
LASKE, DW ;
AKBASAK, A ;
MORRISON, PF ;
DEDRICK, RL ;
OLDFIELD, EH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (06) :2076-2080
[6]
Adeno-associated virus vectors in clinical trials [J].
Carter, BJ .
HUMAN GENE THERAPY, 2005, 16 (05) :541-550
[7]
Variables affecting convection-enhanced delivery to the striatum: a systematic examination of rate of infusion, cannula size, infusate concentration, and tissue-cannula sealing time [J].
Chen, MY ;
Lonser, RR ;
Morrison, PF ;
Governale, LS ;
Oldfield, EH .
JOURNAL OF NEUROSURGERY, 1999, 90 (02) :315-320
[8]
Results from a phase I safety trial of hAADC gene therapy for Parkinson disease [J].
Eberling, J. L. ;
Jagust, W. J. ;
Christine, C. W. ;
Starr, P. ;
Larson, P. ;
Bankiewicz, K. S. ;
Aminoff, M. J. .
NEUROLOGY, 2008, 70 (21) :1980-1983
[9]
Current status of gene therapy trials for Parkinson's disease [J].
Fiandaca, Massimo ;
Forsayeth, John ;
Banklewiez, Krystof .
EXPERIMENTAL NEUROLOGY, 2008, 209 (01) :51-57
[10]
A dose-ranging study of AAV-hAADC therapy in parkinsonian monkeys [J].
Forsayeth, John R. ;
Eberling, Jamie L. ;
Sanftner, Laura M. ;
Zhen, Zhu ;
Pivirotto, Philip ;
Bringas, John ;
Cunningham, Janet ;
Bankiewicz, Krystof S. .
MOLECULAR THERAPY, 2006, 14 (04) :571-577